Novo Gets US FDA Rebuke Over ‘Systemic Failures’ In Drug Safety Reporting

 
• By Manas Mishra
  
Conceptual editorial shot of a red stamp that reads "FDA warning" on a piece of paper.
Novo is undertaking a multi‑pronged effort to address the US FDA's complaints over safety reporting flagged in a warning letter. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Post-Marketing Regulation & Studies

More from United States